OVERVIEW
Stocktwits Top 25 Week 15
Welcome to the Stocktwits Top 25 Newsletter for Week 15 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 15:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
S&P 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (-1.75%) underperformed the S&P 500 index (-1.56%).
There were 4 major changes to the list this week.
Check out how the momentum meter has performed vs. the S&P 500 index.
STOCKTWITS EDGE
Elevate Your Trading Game 👀
Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (-0.98%) underperformed the Nasdaq 100 index (-0.58%).
There were 2 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+3.89%) outperformed the Russell 2000 index (-2.92%).
There were 4 major changes to the list this week.
Top Dawg Of The Week 🐶
The Top 25 lists' Top Dawg was Alpine Immune Sciences, which rallied 84.39%. 📈
The clinical-stage biotech company soared on news that Vertex Pharmaceuticals will acquire it for $65 per share, or $4.90 billion in cash, as the healthcare consolidation trend continues. 💰
The transaction will bolster Vertex Pharmaceuticals’ kidney disease portfolio. Alpine’s lead candidate is being evaluated as a potential treatment for a chronic kidney condition (IgA nephropathy) that affects about 130,000 people in the U.S.
The treatment is expected to enter Phase 3 development in the second half of the year, while the transaction should close in the second quarter. 🗓️
$ALPN is up 237.72% YTD.
Get In Touch
Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲
Help us deliver the best content possible by completing this brief survey. 📝
Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧
Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍
Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍
